Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults
Phase 1
Completed
- Conditions
- Erectile DysfunctionPhosphodiesterase 5 Inhibitor
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 83
- Registration Number
- NCT01967264
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
Phase 2
Withdrawn
- Conditions
- Erectile DysfunctionBenign Prostatic Hyperplasia
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Takeda
- Registration Number
- NCT01967251
Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides
Completed
- Conditions
- Surveillance
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1096
- Registration Number
- NCT01964976
Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea
Completed
- Conditions
- Surveillance
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1101
- Registration Number
- NCT01964950
Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 19192
- Registration Number
- NCT01964963
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 13
- Registration Number
- NCT01953081
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1374
- Registration Number
- NCT01945242
Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"
Completed
- Conditions
- Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3317
- Registration Number
- NCT01945216
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Phase 3
Terminated
- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3494
- Registration Number
- NCT01931566
A Registry for Participants With Chronic Hypoparathyroidism
Active, not recruiting
- Conditions
- Hypoparathyroidism
- Interventions
- Other: No intervention
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1339
- Registration Number
- NCT01922440
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Ohio Health Research Institute, Columbus, Ohio, United States
🇺🇸Alleghany General Hospital, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath